Overview of histiocytic and dendritic disorders by the 5th version of WHO Classifi cation of Hematolymphoid Tumours from 2022

Česká verze

Authors: Z. Adam ¹; M. Hermanová ²; T. Horváth ³; L. Pour ¹; S. Ševčíková ⁴; K. Starý ⁵; M. Dastych ⁵; Z. Řehák ⁶; Z. Adamová ^7,8; Z. Král ¹
Authors place of work: Interní hematologická a onkologická klinika LF MU a FN Brno ¹; I. ústav patologie, LF MU a FN u sv. Anny v Brně ²; Chirurgická klinika LF MU a FN Brno ³; Ústav patologické fyziologie, LF MU Brno ⁴; Interní gastroenterologická klinika LF MU a FN Brno ⁵; Oddělení nukleární medicíny, MOU Brno ⁶; Chirurgické oddělení, Nemocnice ve Frýdku-Místku ⁷; Chirurgické oddělení, Vsetínská nemocnice ⁸
Published in the journal: Klin Onkol 2024; 38(3): 164-177
Category: Přehledy
doi: https://doi.org/10.48095/ccko2024164

Summary

Background: Histiocytoses are rare disorders characterized by the accumulation of macrophages, dendritic cells, or monocyte-derived cells in various tissues and organs of children and adults, with a wide range of clinical manifestations, presentations, and histology. The histiocytoses are classified according to the WHO Classification, the last version of which was published in 2022, or according to the Histiocyte Society Classification, with the last version published in 2016. Purpose: This text provides an overview of histiocytoses as described in the WHO Classification 2022.

Keywords:

5th version of WHO Classification of histiocytic and dendritic neoplasms – Histiocyte Society classification of histiocytic disorders

Zdroje

1. Khoury JD, Solary E, Abla O et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36 (7): 1703–1719. doi: 10.1038/s41375-022-01613-1.

2. Swerdlow SH, Campo E, Harris NL et al. WHO classification of the tumours of haematopoietic and lymphoid tissues. Lyon 2017.

3. Emile JF, Abla O, Fraitag S et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127 (22): 2672–2681. doi: 10.1182/blood-2016-01-690636.

4. Scott GC, Berger R, McKean HE. The role of athmospheric pressure variation in the development of spontaneous pneumothoraces. Am Rev Respir Dis 1989; 139 (3): 659–662. doi: 10.1164/ajrccm/139.3.659.

5. Heimlich HJ. Valve drainage of the pleural cavity. Dis Chest 1968; 53 (3): 282–287. doi: 10.1378/chest.53.3.282.

6. Robinson CL. Autologous blood pleurodesis in recurrent and chronic spontaneous pneumothorax. Can J Surg 1987; 30 (6): 428–429.

7. Sahn SA, Good IT Jr, Potts DE. The pH sclerosing agents: a determinant of pleural symphysis. Chest 1979; 76 (2): 199–200. doi: 10.1378/chest.76.2.198.

8. Daddi N, Vannucci J, Maggio C et al. Efficacy of tigecycline pleurodesis: a comparative experimental study. J Surg Res 2011; 169 (2): e109–e118. doi: 10.1016/ j.jss.2010.07.001.

9. Selikoff IJ, Broder RA, Bader ME et al. Asbestosis and neoplasia. Am J Med 1967; 42 (4): 487–496. doi: 10.1016/0002-9343 (67) 90049-6.

10. Boutin C, Viallant JR, Aeloni Y. Practical thoracoscopy. Springer-Verlag: Berlin 1991.

11. Horvath T, Moravcik P, Mitas L et al. Borderline pneumothorax. Video Assist Thorac Surg 2019; 4: 19. doi: 10.21037/vats.2019.08.02.

12. Doubková M, Adam, Z, Doubek M et al. Diagnostika a léčba plicní formy histiocytózy z Langerhansových buněk. Studia Pneumol Phtiseol 2020; 80 (2): 70–75.

13. Doubková M, Tomíšková M, Skřičková J. Plicní histiocytóza z Langerhansových buněk – nemoc kuřáků. Studia Pneumol Phtiseol 2014; 74 (5): 158–161.

14. Girschikofsky M, Arico M, Castillo D et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis 2013; 8: 72. doi: 10.1186/1750-1172-8-72.

15. Goyal G, Young JR, Koster MJ et al. Mayo clinic histiocytosis working group. The Mayo clinic histiocytosis working group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell, histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc 2019; 94 (10): 2054–2071. doi: 10.1016/j.mayocp.2019.02.023.

16. Goyal G, Tazi A, Go RS et al. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood 2022; 139 (17): 2601–2621. doi: 10.1182/blood.202101434.

17. Kolenová A, Bubanská E, Špotová A et al. Cielená liečba závažnej multisystémovej histiocytózy z Langerhansových buniek. Pediatr Prax 2018; 19 (1): 27–31.

18. Adam Z, Pour L, Tomíška M et al. Histiocytóza z Langerhansových buněk. Přehled příznaků, které přivádějí pacienty k lékařům všech medicínských odborností. Vnitr Lek 2022; 68 (2): e11–e21.

19. Fischer AS, Zaladonis AG, Subrt P et al. Indeterminate cell histiocytosis mimicking rosacea. Cureus 2021; 13 (1): e12850. doi: 10.7759/cureus.12850.

20. Adam Z, Ježová M, Šlampa P et al. Indeterminate cell histiocytosis – disappearance of skin infiltration following electron beam therapy and an application of 2-chlorodeoxyadenosine: case report. Vnitr Lek 2017; 63 (4): 284–288.

21. Lie E, Jedrych J, Sweren R et al. Generalized indeterminate cell histiocytosis successfully treated with methotrexate. JAAD Case Rep 2022; 25: 93–96. doi: 10.1016/ j.jdcr.2022.05.027.

22. Liu T, Cai HC, Cai H et al. Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis. Orphanet J Rare Dis 2022; 17 (1): 39. doi: 10.1186/s13023-022-02193-0.

23. Nakamine H, Yamakawa M, Yoshino T et al. Langerhans cell histiocytosis and Langerhans cell sarcoma: current understanding and differential diagnosis. J Clin Exp Hematop 2016; 56 (2): 109–118. doi: 10.3960/jslrt.56. 109.

24. Rezk SA, Spagnolo DV, Brynes RK et al. Indeterminate cell tumor: a rare dendritic neoplasm. Am J Surg Pathol 2008; 32 (12): 1868–1876. doi: 10.1097/PAS.0b01 3e31818593d6.

25. Xu XL, Bu WB, Zong WK et al. Indeterminate cell histiocytosis: a case series and review of the literature. Eur J Dermatol 2017; 27 (5): 559–561. doi: 10.1684/ejd.2017.3121.

26. Eissa SS, Clay MR, Santiago T et al. Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion. Blood Adv 2020; 4 (13): 2991–2995. doi: 10.1182/bloodadvances.2020001890.

27. Fölster-Holst R. Severe systemic juvenile xanthogranuloma is an indication for systemic therapy. Br J Dermatol 2017; 176 (2): 302–304. doi: 10.1111/bjd.15297.

28. Höck M, Zelger B, Schweigmann G et al. The various clinical spectra of juvenile xanthogranuloma: imaging for two case reports and review of the literature. BMC Pediatr 2019; 19 (1): 128. doi: 10.1186/s12887-019-1490-y.

29. Maintz L, Wenzel J, Irnich M et al. Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2-chlorodeoxyadenosine: case report and review of the literature. Br J Dermatol 2017; 176 (2): 481–487. doi: 10.1111/bjd.14813.

30. Picarsic J, Pysher T, Zhou H et al. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease. Acta Neuropathol Commun 2019; 7 (1): 168. doi: 10.1186/s40478-019-0811-6.

31. Simko SJ, Tran HD, Jones J et al. Clofarabine salvage therapy in refraktory multifocal histiocytic disorders, including Langerhans cell histiocytosis,juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer 2014; 61 (3): 479–487. doi: 10.1002/pbc.24772.

32. Tomás-Velázquez A, Reyes-Múgica M, González-Menchen A et al. Neoadjuvant intralesional methotrexate for juvenile xanthogranuloma in an adult. Dermatol Ther 2022; 35 (1): e15200. doi: 10.1111/dth.15200.

33. Zou T, Wei A, Ma H et al. Systemic juvenile xanthogranuloma: a systematic review. Pediatr Blood Cancer 2023; 70 (5): e30232. doi: 10.1002/pbc.30232.

34. Goyal G, Heaney ML, Collin M et al. Erdheim-Chester disease: consensus recommendations for evaluation, diag- nosis, and treatment in the molecular era. Blood 2020; 135 (22): 1929–1945. doi: 10.1182/blood.2019003507.

35. Al Bayati A, Plate T, Al Bayati M et al. Dabrafenib and trametinib treatment for Erdheim-Chester disease with brain stem involvement. Mayo Clin Proc Innov Qual Outcomes 2018; 2 (3): 303–308. doi: 10.1016/ j.mayocpiqo.2018.05.001.

36. Cohen Aubart F, Emile JF, Carrat F et al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood 2017; 130 (11): 1377–1380. doi: 10.1182/blood-2017-03-771873.

37. Cohen-Aubart F, Emile JF, Carrat F et al. Phenotypes and survival in Erdheim-Chester disease: results from a 165-patient cohort. Am J Hematol 2018; 93 (5): E114–E117. doi: 10.1002/ajh.25055.

38. Franconieri F, Deshayes S, de Boysson H et al. Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment. Oncoimmunology 2018; 7 (8): e1450712. doi: 10.1080/2162402X.2018.1450712.

39. Hao X, Feng R, Bi Y et al. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis. J Neurosurg Pediatr 2018; 23 (1): 48–53. doi: 10.3171/2018.6.PEDS17728.

40. Haroche J, Cohen-Aubart F, Amoura Z. Erdheim-Chester disease. Blood 2020; 135 (16): 1311–1318. doi: 10.1182/blood.2019002766.

41. Král Z, Krejčí M, Ježová M et al. Léčba Erdheimovy--Chesterovy choroby. Trans Hematol Dnes 2020; 26 (4): 271–277.

42. Oneal PA, Kwitkowski V, Luo L et al. FDA approval summary: vemurafenib for the treatment of patients with Erdheim-Chester disease with the BRAFV600 mutation. Oncologist 2018; 23 (12): 1520–1524. doi: 10.1634/theoncologist.2018-0295.

43. Tamura S, Kawamoto K, Miyoshi H et al. Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: a case report. J Clin Exp Hematop 2018; 58 (4): 161–165. doi: 10.3960/jslrt.18015.

44. Adam Z, Szturz P, Pour L et al. Cladribine is highly effective in the treatment of Langerhans cell histiocytosis and rare histiocytic disorders of the juvenile xanthogranuloma group. Vnitr Lek 2012; 58 (6): 455–465.

45. Abla O, Jacobsen E, Picarsic J et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood 2018; 131 (26): 2877–2890. doi: 10.1182/blood-2018-03-839753.

46. Adam Z, Adamová Z, Pour L et al. Rosai-Dorfman-Destombesova choroba – histiocytární onemocnění se zánětlivými projevy. Klin Onkol 2022; 35 (4): 262–270. doi: 10.48095/ccko2022262.

47. Averitt AW, Heym K, Akers L et al. Sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman disease): diagnostic and treatment modalities for this rare entity revisited. J Pediatr Hematol Oncol 2018; 40 (4): e198–e202. doi: 10.1097/MPH.0000000000001044.

48. Golwala ZM, Taur P, Pandrowala A et al. Sirolimus-A targeted therapy for Rosai-Dorfman disease. Pediatr Blood Cancer 2019; 66 (12): e27994. doi: 0.1002/pbc.27994.

49. Tirado-Sánchez A. Recalcitrant primary cutaneous Rosai-Dorfman disease. Efficacy of sirolimus and intralesional methylprednisolone. Skin Health Dis 2023; 3 (5): e273. doi: 10.1002/ski2.273.

50. Ghawas MS, Ng T, Chen LYC. Confirmed efficacy of lenalidomide and dexamethasone in unresectable cutaneous facial Rosai-Dorfman-Destombes disease. Mayo Clin Proc Innov Qual Outcomes 2019; 3 (1): 94–96. doi: 10.1016/j.mayocpiqo.2018.11.002.

51. Go RS, Jacobsen E, Baiocchi R et al. Histiocytic neoplasms, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021; 19 (11): 1277–1303. doi: 10.6004/jnccn.2021.0053.

52. Hasegawa M, Sakai F, Okabayashi A et al. Rosai-Dorfman disease of the lung overlapping with IgG4-related disease: the difficulty in its differential diagnosis. Intern Med 2017; 56 (8): 937–941. J Clin Pathol 2020; 73 (11): 697–705. doi: 10.1136/jclinpath-2020-206733.

53. Jacobsen E, Shanmugam V, Jagannathan J. Rosai-Dorfman disease with activating KRAS mutation – response to cobimetinib. N Engl J Med 2017; 377 (24): 2398–2399. doi: 10.1056/NEJMc1713676.

54. Kemps PG, Picarsic J, Durham BH et al. ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood 2022; 139 (2): 256–280. doi: 10.1182/blood.2021013338.

55. Guo Y, Qu HB, Ning G et al. Case report: ALK-positive histiocytosis with <i>KIF5B-ALK</i> fusion in cerebrum-disseminated lesions in a child. Front Oncol 2022; 12: 858939. doi: 10.3389/fonc.2022.858939.

56. Liu W, Liu HJ, Wang WY et al. Multisystem ALK-positive histiocytosis: a multi-case study and literature review. Orphanet J Rare Dis 2023; 18 (1): 53. doi: 10.1186/s13023-023-02649-x.

57. Kommalapati A, Tella SH, Go RS et al. Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma. Leuk Lymphoma 2019; 60 (2): 553–555. doi: 10.1080/10428194.2018.1492128.

58. Branco B, Comont T, Ysebaert L et al. Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: a case report and review of the literature. Eur J Haematol 2019; 103 (4): 444–448. doi: 10.1111/ejh.13303.

59. Farris M, Hughes RT, Lamar Z et al. Histiocytic sarcoma associated with follicular lymphoma: evidence for dramatic response with rituximab and bendamustine alone and a review of the literature. Clin Lymphoma Myeloma Leuk 2019; 19 (1): e1–e8. doi: 10.1016/j.clml.2018.10. 004.

60. Gounder MM, Solit DB, Tap WD. Trametinib in histiocytic sarcoma with an activating MAP2K1 (MEK1) mutation. N Engl J Med 2018; 378 (20): 1945–1947. doi: 10.1056/NEJMc1511490.

61. Chohan KL, Abeykoon JP, Young JR et al. Sirolimus as frontline therapy for PTEN-mutated histiocytic sarcoma. Haematologica 2023; 108 (6): 1702–1706. doi: 10.3324/haematol.2022.282207.

62. Imataki O, Uemura M, Fujita H et al. Aplication of PD-L1 blockade in refractory histiocytic sarcoma: a case report. Mol Clin Oncol 2022; 17 (3): 136. doi: 10.3892/mco.2022.2569.

63. Massoth LR, Hung YP, Ferry JA et al. Histiocytic and dendritic cell sarcomas of hematopoietic origin share targetable genomic alterations distinct from follicular dendritic cell sarcoma. Oncologist 2021; 26 (7): e1263–e1272. doi: 10.1002/onco.13801.

64. Montalvo N, Lara-Endara J, Redrobán L et al. Primary splenic histiocytic sarcoma associated with hemophagocytic lymphohistiocytosis: a case report and review of literature of next-generation sequencing involving FLT3, NOTCH2, and KMT2A mutations. Cancer Rep (Hoboken) 2022; 5 (5): e1496. doi: 10.1002/cnr2.1496.

65. Takada M, Hix JML, Corner S et al. Targeting MEK in a translational model of histiocytic sarcoma. Mol Cancer Ther 2018; 17 (11): 2439–2450. doi: 10.1158/1535-7163.MCT-17-1273.

66. Venkataraman V, Massoth LR, Sullivan RJ et al. Secondary histiocytic sarcoma with BRAF<sup>V600E</sup> mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapy. Pediatr Blood Cancer 2021; 68 (10): e29166. doi: 10.1002/pbc.29166.

67. Voruz S, Cairoli A, Naveiras O et al. Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma. Haematologica 2018; 103 (1): e39–e41. doi: 10.3324/haematol.2017.179150.

68. Zhao Y, Deng Y, Jiang Y et al. Case report: targeting the PD-1 receptor and genetic mutations validated in primary histiocytic sarcoma with hemophagocytic lymphohistiocytosis. Front Immunol 2023; 14: 1127599. doi: 10.3389/fimmu.2023.1127599.

69. Viñas-Giménez L, Padilla N, Batlle-Masó L et al. A comprehensive database on the molecular basis of familial hemophagocytic lymphohistiocytosis. Front Immunol 2020; 11: 107. doi: 10.3389/fimmu.2020.00107.

70. Ponnatt TS, Lilley CM, Mirza KM. Hemophagocytic lymphohistiocytosis. Arch Pathol Lab Med 2022; 146 (4): 507–519. doi: 10.5858/arpa.2020-0802-RA.

71. Koumadoraki E, Madouros N, Sharif S et al. Hemophagocytic lymphohistiocytosis and infection: a literature review. Cureus 2022; 14 (2): e22411. doi: 10.7759/cureus.22411.

72. Masood A, Wahab A, Clifford T et al Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient – a case report. Clin Case Rep 2021; 9 (12): e05184. doi: 10.1002/ccr3.5184.

73. Kim DW, Bukhari A, Lutfi F et al. Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma 2022; 63 (6): 1339–1347. doi: 10.1080/10428194.2021.2024817.

74. Suková M, Mejstříková E, Vodičková E et al. Hemofagocytující lymfohistiocytóza. Vnitr Lek 2010; 56 (Suppl 2): 157–169.

75. Daver N, McClain K, Allen CE et al. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer 2017; 123 (17): 3229–3240. doi: 10.1002/cncr.30826.

76. Hystiocytosis association. [online]. Available from: www.histio.org.

77. Hines MR, von Bahr Greenwood T, Beutel G et al. Consensus-based guidelines for the recognition, diagnosis, and management of hemophagocytic lymphohistiocytosis in critically ill children and adults. Crit Care Med 2022; 50 (5): 860–872. doi: 10.1097/CCM.0000000000005 361.

78. Jordan MB, Allen CE, Greenberg J et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer 2019; 66 (11): e27929. doi: 10.1002/pbc.27929.

79. La Rosée P, Horne A, Hines M et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019; 133 (23): 2465–2477. doi: 10.1182/blood.2018894618.

80. Ehl S, Astigarraga I, von Bahr Greenwood T et al. Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH Steering Committee of the Histiocyte Society. J Allergy Clin Immunol Pract 2018; 6 (5): 1508–1517. doi: 10.1016/j.jaip.2018.05.031.

81. Taylor ML, Hoyt KJ, Han J et al. An evidence-based guideline improves outcomes for patients with hemophagocytic lymphohistiocytosis and macrophage activation syndrome. J Rheumatol 2022; 49 (9): 1042–1051. doi: 10.3899/jrheum.211219.

82. La Rosée P, Horne A, Hines M et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019; 133 (23): 2465–2477. doi: 10.1182/blood.2018894618.

83. Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key. Open Access Rheumatol 2018; 10: 117–128. doi: 10.2147/OARRR.S151013.